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Objective: To investigate the association with white blood cell (WBC) and 
atherosclerotic parameters including cardio-ankle vascular index (CAVI) and carotid 
intima-media thickness (CIMT) in the general population.  
Methods: We investigated the relationship between WBC count and metabolic 
syndrome components, CAVI, CIMT in 3738 Japanese study participants.  
Results: WBC count weakly correlated with CAVI in men (= 0.61, p = 0.043), but not 
in women (= 0.35, p = 0.17). On the other hand, WBC did not correlate with CIMT in 
either men or women (p = 0.41 and p = 0.71, respectively). 
Conclusion: WBC count was associated with lipids, blood pressure and body mass 





White blood cells (WBC) comprise an inexpensive and reliable marker of 
inflammation that is universally applied in standard clinical practice. Recently 
atherosclerosis has been recognized as an active, inflammatory process (Ross 1999), 
and has been discussed whether the elevation of WBC is merely a marker of 
inflammation, whether it directly enhances atherosclerosis and thrombosis, or both. It is 
still remained unclear whether a relationship between WBC and subclinical 
atherosclerosis exists. Several studies have shown a positive and independent 
association between WBC and specific diseases including cancer (Grimm et al. 1985 
and Friedman et al. 1991), cardiovascular disease (CVD) (Grimm et al. 1985 and 
Prentice et al. 1982), stroke (Prentice et al. 1982) and all-cause mortality (Grimm et al. 
1985). Furthermore, Lao et al. recently identified a strong relationship between total 
WBC count and the constellation of metabolic syndrome components in an older 
Chinese population (Lao et al. 2008). Therefore, detecting a high WBC count or a 
change in the count might be important in predicting subsequent disease. 
Recent advances in medical technology have allowed noninvasive assessment of 
early atherosclerosis (Vogel et al. 2000 and Bots et al. 2002). High-resolution B-mode 
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ultrasonography provides a noninvasive method of measuring arterial wall thickening, 
and indeed, this modality has shown that carotid intima-media thickness (CIMT) is a 
powerful predictor of CVD (Bots et al. 2002), as it correlates with generalized 
atherosclerosis, myocardial infarction and stroke (Bots et al. 1997). Population studies 
have revealed that traditional cardiovascular risk factors such as age, smoking, 
low-density lipoprotein-cholesterol (LDL-C) and elevated blood pressure (BP) are 
closely associated with CIMT (Loimaala et al. 2006). 
Pulse wave velocity (PWV) is a noninvasive clinical index of aortic stiffness (van 
Popele et al. 2001), and it can predict cardiovascular events as well as all-cause 
mortality in hypertensive patients and in the general population (Blacher et al. 1999 and 
Shokawa et al. 2005). The novel cardio-ankle vascular index (CAVI), which reflects the 
stiffness of the aorta, femoral artery and tibial artery, involves the measurement of 
brachial-ankle PWV and BP (Yambe et al. 2004 and Shirai et al. 2006). This index is 
essentially independent of changes in BP during the examination, but closely correlates 
with systolic BP. Kadota et al. suggested that CAVI, like PWV, can serve as a marker of 
the increase in central artery stiffness with age (Kadota et al. 2008). Although 
Wakabayashi et al. revealed a correlation between WBC and CAVI in patients with type 
2 diabetes mellitus (Wakabayashi et al. 2006), this aspect has not been investigated in 
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the general population. 
In this present study, we investigated the association with WBC and atherosclerotic 





The Special Committee of Nagasaki University provided ethical approval to proceed 
with this study (project registration number 0501120073), during a medical screening 
program for the general population over 20 years old, residing in Goto City (total 
population, 41,729 in 2008), Nagasaki Prefecture, Japan between 2005 and 2009. Data 
were collected by the staff of Nagasaki University, in cooperation with the staff of Goto 
city. We obtained written, informed consent from 4992 Japanese adults (1640 men and 
3352 women) to participate in the study. However, 51 of them with severe 
hypertriglycemia (>4.0 g/l) and 1203 in whom WBC, CAVI and CIMT were not 
measured were excluded from the study. Data from a total of 3738 participants (1165 
men and 2573 women) were finally included for further analysis. 
The height and weight of each participant were measured and body mass index (BMI: 
kilograms per meter square) was calculated as an index of obesity. Waist circumference 
(WC) was measured horizontally at the umbilicus with a tape measure after normal 
expiration. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
recorded at rest. Mean blood pressure (MBP) was calculated as DBP + (SBP-DBP)/3. 
Blood samples were collected from each participant after an overnight fast. Serum 
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and plasma were separated and stored at -20°C and -80°C, respectively, until assay. 
Both white (WBC) and red (RBC) blood cells were counted, and hemoglobin (HGB) 
and hematocrit (HCT) were measured using standard laboratory procedures. Serum 
concentrations of total cholesterol (TC), triglyceride (TG), and high-density 
lipoprotein-cholesterol (HDL-C) were also measured using standard laboratory 
procedures and LDL-C was calculated using the Friedewald equation (Friedewald et al. 
1972). In addition, hemoglobin A1c (HbA1c), serum creatinine (CRE) and uremic acid 
(UA) were measured using standard laboratory procedures. 
The physicians (Y.S., N.H., M.N. and N.T.) measured CIMT by ultrasonography of 
the right and left carotid arteries using a LOGIC Book XP with a 10-MHz linear array 
transducer (GE Medical Systems, Milwaukee, WI, USA). The far wall of the carotid 
artery was displayed on a longitudinal two-dimensional ultrasonographic image as two 
bright white lines separated by a hypoechoic space. The distance from the leading edge 
of the first (lumen-intima interface), to the leading edge of the second (media-adventitia 
interface) bright line was identified as the CIMT. Images obtained were stored on the 
hard disk of the ultrasound system, and were analyzed using Intima Scope software 
(MEDIA CROSS, Tokyo, Japan). Averages of the right and left CIMT were calculated 
and used in the analysis. Intra- (N.T., n = 32) and inter- (N.T. vs. M.N., n = 41) observer 
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variations in CIMT were 0.91 (p < 0.01) and 0.78 (p < 0.01), respectively. 
The CAVI in supine participants was recorded using a VaseraVS-1000 vascular 
screening system (Fukuda Denshi, Tokyo, Japan). The principles underlying CAVI have 
been described by Yambe et al. (Yambe et al. 2004). Electrocardiographic electrodes are 
placed on both wrists, a microphone for detecting heart sounds is placed on the sternum, 
and cuffs are wrapped around both arms and ankles to obtain automatic measurements. 
The data were then analyzed using VSS-10 software (Fukuda Denshi), and calculated 
averaged values for the right and left CAVI further analyzed. 
Results are expressed as means ± standard deviation or median (25th - 75th quartile). 
Differences in laboratory values between men and women were evaluated using a t-test 
and the Mann-Whitney U-test. Smoking status was analyzed among three groups; i.e. 
current smoker, past smoker and never smoked. Differences in the smoking status and 
the ratio of current treatment for hypertension (HT), diabetes mellitus (DM) and 
dyslipidemia (DL) were evaluated using the χ2 test. White blood cells and other 
variables including laboratory values, CAVI and CIMT were evaluated using univariate 
linear regression analysis. Multivariate linear regression analysis was adjusted for age to 
evaluate WBC and other existing parameters. We evaluated associations between WBC 
and CAVI, CIMT using another multivariate linear regression analysis adjusted for age 
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and other confounding factors such as BMI, MBP, HbA1c HDL-C. To confirm whether 
relationships between WBC and CAVI, CIMT are independent of circulation dynamics, 
lipid metabolism and glucose metabolism, multivariate linear regression analysis was 
adjusted for age, BMI, MBP, HbA1c, HDL-C and current treatment for HT and/or DM 
and/or DL. Because the distribution of TG was skewed, logarithmic transformation was 
performed for the univariate and multivariate linear regression analyses. Probability 
values below 0.05 were considered indicative of statistical significance. All data were 





Table 1 shows the characteristics of the study participants. The men were 
significantly older than the women (average: 66.0 ± 10.9 vs. 64.0 ± 11.2 years, p < 0.01). 
Besides age, BMI, WC, MBP, WBC, RBC, HGB, HCT, CRE, UA, TC, TG, HDL-C, 
LDL-C, CAVI and CIMT, as well as the ratio of current smoker, past smoker and 
current treatment for DM and DL, significantly differed between men and women. The 
number of participants who are diagnosed as HT, DM and DL though not under drug 
treatment were 12, 24 and 31 respectively in the whole participants. 
Univariate linear regression analysis showed that WBC correlated in men and in 
women with age, BMI, WC, MBP, RBC, HGB, HCT, UA, TC, log TG, HDL-C, LDL-C 
and HbA1c. In addition, smoking status in men, and CRE in women also correlated 
(Table 2). This analysis revealed that WBC did not correlate with CAVI and CIMT in 
either men or women. 
Multivariate linear regression analysis adjusted for age revealed that WBC correlated 
with BMI, WC, smoking status, MBP, RBC, HGB, HCT, CRE, UA, TC, log TG, 
HDL-C, LDL-C, HbA1c, CAVI and CIMT in men. In women, WBC correlated with the 
same parameters except for smoking status, CAVI and CIMT (Table 3). 
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Multivariate linear regression analysis adjusted for confounding factors including 
CAVI showed that WBC correlated with age (= -0.19, p < 0.001), BMI (= 0.64, p < 
0.001), smoking status (= 5.1, p < 0.001), and HDL-C (= -0.093, p = 0.002) in men, 
and with age (= -0.18, p < 0.001), BMI (= 0.33, p < 0.001), MBP (= 0.049, p = 
0.025), HbA1c (= 1.1, p = 0.017) and HDL-C (= -0.075, p < 0.001) in women (Table 
4). The WBC count weakly correlated with CAVI in men (= 0.61, p = 0.043) though 
not in women (= 0.35, p = 0.17). In the whole participants, WBC correlated in all 
confounding factors and also with CAVI (= 0.4, p = 0.028). Furthermore, multivariate 
linear regression analysis adjusted for confounding factors including current treatment 
for HT and/or DM and/or DL showed that WBC did not correlate with CAVI in men, 
women and all (p = 0.059, p = 0.27 and p = 0.063, respectively; data not shown). 
Multivariate linear regression analysis adjusted for confounding factors including 
CIMT showed that WBC correlated with age (= -0.17, p < 0.001), BMI (= 0.62, p < 
0.001), smoking status (= 5.1, p < 0.001), MBP (= 0.072, p = 0.036), and HDL-C 
(= -0.094, p = 0.002) in men, and with age (= -0.16, p < 0.001), BMI (= 0.32, p < 
0.001), MBP (= 0.052, p = 0.019), HbA1c (= 1.2, p = 0.013), and HDL-C (= -0.075, 
p < 0.001) in women. WBC did not correlate with CIMT in either men or women (p = 
0.41 and p = 0.71, respectively; Table 5). In the whole participants, WBC correlated in 
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all confounding factors, although it did not correlate with CIMT (= 1.2, p = 0.51). 
Multivariate linear regression analysis adjusted for confounding factors including 
current treatment for HT and/or DM and/or DL also showed that WBC did not correlate 






In this study, we showed that the WBC count weakly correlated with CAVI in men 
but not in women and that it did not correlate with CIMT in either gender after 
adjustment for confounding factors. To our knowledge, this is the first analysis of the 
relationship between WBC and atherosclerosis represented by CIMT and CAVI in a 
large community-based sample. We also showed that WBC was strongly correlated with 
metabolic syndrome markers such as BMI, WC, MBP, HbA1c, TC, LDL-C and HDL-C, 
which is consistent with the findings of Lao et al. (Lao et al. 2008). Their report also 
showed that the prevalence of metabolic syndrome significantly increased with higher 
WBC counts in both genders. 
Our results showed a positive association between BMI and WBC, which is also 
consistent with previous findings (Saito et al. 2003). Obesity plays an important role in 
the pathogenesis of atherosclerosis through low-grade, chronic inflammation. Elevated 
free fatty acids associated with obesity, insulin resistance, DM and metabolic syndrome 
cause endothelial dysfunction by activating innate immune inflammatory pathways 
upstream of the nuclear transcription factor, nuclear factor-kappaB (NF-B) (Vincent et 
al. 2003), which promotes the synthesis and release of pro-inflammatory cytokines that 
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enhance the attachment of monocytes and macrophages to the vessel walls [21]. 
Damage to the vessel walls causes endothelium and smooth muscle cells to become 
transcriptionally active and synthesize pro-inflammatory proteins, including 
chemokines, cell adhesion molecules and cytokines. 
Smoking is known as a risk factor for atherosclerosis. In our study, WBC associated 
with smoking status in men though not in women. This is probably due to the small 
number of smokers in women. Previous studies showed that there is a strong, positive 
relationship between the number of cigarettes smoked and WBC count (Hansen et al. 
1990 and Petitti et al. 1986). 
Shankar et al. showed that the WBC count is associated with incidental hypertension 
in both genders independently of smoking and most traditional cardiovascular risk 
factors in a predominantly Caucasian cohort (Shankar et al. 2004). We found here that 
WBC also correlated with blood pressure in Japanese subjects. The concentration of the 
vasoconstrictor angiotensin II is often elevated in hypertensive patients. Angiotensin II 
can also contribute to atherogenesis by stimulating the growth of smooth muscle and its 
lipoxygenase activity, which can increase inflammation and LDL-C oxidation (Ross 
1999). 
The WBC count significantly correlates with HbA1c in both DM and non-DM 
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patients with known coronary atherosclerosis, and this indicates an early association 
between glycemia, inflammation and atherosclerosis before DM develops (Gustavsson 
et al. 2004). We also found a correlation between WBC and HbA1c, which suggests that 
low-grade chronic inflammatory activity increases in hyperglycemia. One possible 
explanation for this is that both a higher WBC count and insulin resistance reflects 
underlying activation of the immune system. Diabetes mellitus is considered to be 
associated with activation of the innate immune system, and acute-phase reactants, such 
as C-reactive protein and sialic acid, are proposed predictors of the risk of developing 
type 2 DM (Crook 2004). A chronic inflammatory response involved in the 
atherosclerosis process might increase blood concentrations of acute-phase reactants 
including WBC. Cytokines such as interleukin-6, which is a potent WBC differentiation 
factor, are associated with insulin resistance (Fernandez-Real et al. 1997). Activation of 
the immune system caused by inflammation could increase WBC, and cytokine 
production might therefore decrease insulin sensitivity. 
We found that TG and LDL-C were positively associated with WBC and that 
HDL-C was inversely associated. Wilson et al. identified a relationship between 
lipoprotein cholesterol levels and WBC in the Framingham heart study (Wilson et al. 
1983); an elevated WBC count was associated with decreased HDL-C and increased 
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LDL-C in both smokers and non-smokers, suggesting that a higher WBC count is 
related to a more atherogenic lipid factor. A major cause of damage to the endothelium 
and underlying smooth muscle is LDL-C. Particles of LDL-C trapped in an artery 
undergo progressive oxidation and engulfment by macrophages through scavenger 
receptors on the surfaces of the endothelium and smooth muscle cells. Oxidized LDL-C 
is a feature of atherosclerotic lesions. 
White blood cells play a crucial role in initiating and propagating the atherosclerotic 
process (Shankar et al. 2004). Stimulated WBC have an increased tendency to adhere to 
the vascular endothelium and easily penetrate the intima, causing capillary leukocytosis 
and increased vascular resistance. Additionally, WBC release various hydrolytic 
enzymes, cytokines and growth factors that can induce further vascular damage (Ross 
1999). This cascade causes endothelial dysfunction and alters arterial elastic properties, 
leading to structural stiffness. 
Lee et al. reported a positive association between WBC and baPWV that was 
independent of classical cardiovascular risk factors (Lee et al. 2009). On the other hand, 
we showed a weak correlation between WBC and CAVI in men (= 0.61, p = 0.043), 
but not in women (= 0.35, p = 0.17). This might be associated with the recognized sex 
difference in the mechanism and pathophysiology of atherosclerosis (Huang et al. 2001). 
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Furthermore, we found that WBC did not correlate with CIMT in either men or women, 
which is inconsistent with previous studies (Loimaala et al. 2006 and Magyar et al. 
2003). Magyer et al. showed that the WBC count was significantly higher in patients 
with at least 30% internal carotid artery stenosis or occlusion than in controls, and that 
CIMT was increased in such patients compared with controls. In addition, WBC still 
correlated with CIMT after adjusting for lipid factors (Magyar et al. 2003). This 
contradiction might be due to the background of the study population and the method of 
statistical analyses. Further studies are needed to clarify the association between WBC 
and atherosclerosis represented by CAVI and CIMT. 
Our study has some limitations. First, only one WBC measurement was included in 
the analysis, and whether an acute, brief inflammatory episode or chronic inflammation 
was responsible for the observed correlation could not be discriminated. We could not 
fully exclude individuals with relevant inflammation or infection, but although WBC 
varies from day to day (Pocock et al. 1989), a single measurement can nevertheless 
predict the risk of death and of specific diseases, including cancer and CVD (Hoffman 
et al. 2004 and Madjid et al. 2004). Secondly, we did not estimate the data of other acute 
inflammatory markers such as CRP and fibrinogen. Thirdly, we did not analyze by 
comparing participants with or without current treatments due to the relatively small 
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number of participants who are not under drug treatment. At last, we only evaluated the 





We showed that the WBC count is strongly associated with metabolic syndrome 
components such as lipids, blood pressure and BMI, whereas correlations with CAVI 
and CIMT were weak or absent. Further evaluation is needed to clarify the value of the 
WBC count as a marker of atherosclerosis.
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Table 1. Characteristics of the study participants. 
 
   Men (n = 1165)   Women (n = 2573) All (n = 3738) 
Age (y)   66.0±10.9   64.0±11.2*  64.6±11.2 
BMI (kg/m2)  23.5±3.2   22.9±3.4*  23.1±3.4 
WC (cm)  85.0±8.7   81.2±9.9*  82.4±9.7 
MBP (mmHg)  103.0±12.9   102.1±13.1*  102.7±13.1 
WBC (109 cells/l) 6.0±1.5    5.7±1.4*  5.8±1.4 
RBC (1010 cells/l) 457.3±43.9   424.8±36.8*  434.9±41.9 
HGB (g/l)  143.3±12.9   128.6±11.3*  133.0±13.6 
HCT (%)  43.9±3.8   40.0±3.3*  41.2±3.9 
CRE (mg/l)  9.2±2.6    7.1±1.7*  7.8±2.3 
UA (g/l)   61.5±13.9   48.7±12.2*  52.7±14.1 
TC (g/l)   1.9±0.3    2.1±0.3*  2.1±0.3 
TG (g/l)   1.1 (0.75-1.6)   1.0 (0.73-1.5)* 1.0 (0.74-1.5) 
HDL-C (g/l)  0.55±0.15   0.62±0.15*  0.59±0.15 
LDL-C (g/l)  1.1±0.3    1.3±0.3*  1.2±0.3 
HbA1c (%)  5.3±0.6    5.2±0.6  5.2±0.6 
CAVI   8.5±1.6    8.1±1.4*  8.2±1.5 
CIMT (mm)  0.73 (0.64-0.82)   0.69 (0.61-0.78)* 0.70 (0.62-0.80) 
Current smoker  264(22.7%)   86(3.3%)*  350(9.4%) 
Past smoker  445(38.2%)   48(1.9%)*  493(13.2%) 
HT   337 (29.0%)   704 (27.4%)  1041 (27.8%) 
DM   69 (5.9%)   88 (3.4%)*  157 (4.2%) 
DL   62 (5.3%)   263 (10.2%)*  325 (8.7%) 
Values are means ± standard deviation or median (25th-75th percentile). 
BMI, body mass index; WC, waist circumference; MBP, mean blood pressure; WBC, 
white blood cells; RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit; CRE, 
creatinine; UA, uric acid; TC, total cholesterol; TG, triglyceride; HDL-C, high-density 
lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; HbA1c, hemoglobin 
A1c; CAVI, cardio-ankle vascular index; CIMT, carotid intima-media thickness; HT, 
under treatment for hypertension; DM, under treatment for diabetes mellitus; DL, under 
treatment for dyslipidemia.  




Table 2. Univariate linear regression analysis of WBC and other variables. 
 
Variables  Men    Women    All 
    Correlation P-value  Correlation P-value  Correlation P-value 
Age   0.15†  <0.001  -0.076†  <0.001  -0.092†  <0.001 
BMI   0.18†  <0.001  0.11†  <0.001  0.14†  <0.001 
WC   0.2†  <0.001  0.1†  <0.001  0.14†  <0.001 
Smoking status  0.272†  <0.001  -0.016  0.41  0.2†  <0.001 
MBP   0.1†  0.001  0.043*  0.031  0.069†  <0.001 
RBC   0.19†  <0.001  0.16†  <0.001  0.19†  <0.001 
HGB   0.21†  <0.001  0.13†  <0.001  0.18†  <0.001 
HCT   0.21†  <0.001  0.15†  <0.001  0.19†  <0.001 
CRE   0.034  0.25  0.078†  <0.001  0.092†  <0.001 
UA   0.095†  0.001  0.13†  <0.001  0.14†  <0.001 
TC   0.096†  0.003  0.053†  0.007  0.035*  0.046 
logTG   0.26†  <0.001  0.2†  <0.001  0.22†  <0.001 
HDL-C   -0.13†  <0.001  -0.094†  <0.001  -0.12†  <0.001 
LDL-C   0.079†  0.007  0.053†  0.008  0.044†  0.007 
HbA1c   0.072*  0.014  0.053
†  0.007  0.062†  <0.001 
CAVI   0.001  0.98  -0.019  0.33  0.003  0.868 
CIMT   -0.009  0.77  -0.018  0.37  -0.002  0.916 
*p < 0.05; †p < 0.01. 
29 
 
Table 3. Multivariate linear regression analysis of WBC adjusted for age. 
 
Variables Men         Women         All 
   95%CI  P-value       95%CI       P-value       95%CI      P-value 
   0.49, 1.0 <0.001      0.48    0.32, 0.63       <0.001      0.6     0.47, 0.73      <0.001
WC  0.33 0.23, 0.43 <0.001      0.17    0.12, 0.23       <0.001      0.24    0.19, 0.28      <0.001 
Smoking status 5.1 4.0, 6.2  <0.001      0.0     -0.001, 0.0      0.32      4.3     3.6, 5.0        <0.001 
MBP  0.12 0.057, 0.19 <0.001      0.077   0.035, 0.12     <0.001      0.1     0.067, 0.14     <0.001 
RBC  0.054 0.033, 0.075 <0.001      0.055   0.041, 0.07     <0.001      0.061   0.05, 0.072     <0.001 
HGB  2.1 1.4, 2.8  <0.001      1.5     1.0, 2.0       <0.001      1.8     1.5, 2.2      <0.001 
HCT  0.72 0.48, 0.96 <0.001      0.59    0.43, 0.75       <0.001      0.68    0.57, 0.8      <0.001 
CRE  4.0 0.59, 7.4 0.022      7.1     4.0, 10.2       <0.001      0.7     5.0, 9.1      <0.001 
UA  1.0 0.39, 1.6 0.002      1.6     1.1, 2.0       <0.001      1.6     1.3, 1.9    <0.001 
TC  0.031 0.003, 0.059 0.032      0.023   0.007, 0.38      0.004    0.013   -0.001, 0.027    0.059 
logTG  15.4 11.8, 19.0 <0.001      13.2    10.9, 15.6       <0.001      14.3    12.4, 16.3      <0.001 
HDL-C  -0.15 -0.21, -0.087 <0.001      -0.099  -0.13, -0.064     <0.001      -0.13   -0.16, -0.1      <0.001 
LDL-C  0.032 0.002, 0.061 0.036      0.026   0.009, 0.043     0.003      0.021   0.006, 0.035     0.006 
HbA1c  2.2 0.82, 3.6 0.002      1.7     0.77, 2.6       <0.001      1.9     1.2, 2.7      <0.001 
CAVI  0.85 0.24, 1.5 0.007      0.32    -0.13, 0.78      0.17      0.68    0.32, 1.0       <0.001 
CIMT  6.8 0.58, 12.9 0.032      2.7     -1.7, 7.1       0.23      5.4     1.9, 9.0       0.003 
, standardized regression coefficient; CI, confidence interval. Other abbreviations are as shown in Table 1. 
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Table 4. Multivariate linear regression analysis of WBC adjusted for confounding factors including CAVI. 
 
Variables Men         Women         All 
   95%CI  P-value        95%CI  P-value       95%CI      P-value 
Age  -0.19  -0.28, -0.1 <0.001      -0.18 -0.23, -0.12 <0.001      -0.18    -0.23, -0.13    <0.001 
BMI  0.64  0.35, 0.93 <0.001      0.33 0.17, 0.5 <0.001      0.42     0.27, 0.56     <0.001 
Smoking status 5.1  4.0, 6.2 <0.001      -5.7 -0.001, 0.001 0.88      3.9      3.2, 4.6       <0.001 
MBP  0.066  -0.002, 0.13 0.055      0.049 0.006, 0.092 0.025      0.059    0.023, 0.096    0.001 
HbA1c  0.9  -0.45, 2.3 0.19      1.1 0.2, 2.1        0.017       1.2       0.4, 1.9       0.003 
HDL-C  -0.093  -0.15, -0.034 0.002      -0.075 -0.11, -0.04 <0.001      -0.077   -0.11, -0.047   <0.001 
CAVI  0.61  0.06, 1.3 0.043      0.35 -0.14, 0.78 0.17      0.4      0.044, 0.76     0.028 
, standardized regression coefficient; CI, confidence interval. Other abbreviations are as shown in Table 1. 
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Table 5. Multivariate linear regression analysis of WBC adjusted for confounding factors including CIMT. 
 
Variables Men         Women         All 
   95%CI  P-value        95%CI  P-value       95%CI      P-value 
Age  -0.17  -0.25, -0.078 <0.001      -0.16 -0.22, -0.1 <0.001      -0.16    -0.21, -0.12    <0.001 
BMI  0.62  0.33, 0.91 <0.001      0.32 0.15, 0.49 <0.001      0.4      0.26, 0.55     <0.001 
Smoking status 5.1  4.0, 6.2 <0.001      -6.9 -0.001, 0.001 0.85      3.9      3.2, 4.6       <0.001 
MBP  0.072  0.005, 0.14 0.036      0.052 0.008, 0.095 0.019      0.063    0.027, 0.099    0.001 
HbA1c  1.0  -0.35, 2.4 0.15      1.2 0.25, 2.1 0.013      1.2      0.46, 2.0       0.002 
HDL-C  -0.094  -0.15, -0.034 0.002      -0.075 -0.11, -0.04 <0.001      -0.078   -0.11, -0.048   <0.001 
CIMT  2.5  0.06, 1.3 0.41      0.84 -0.14, 0.78 0.71      1.2      0.044, 0.76     0.51 
, standardized regression coefficient; CI, confidence interval. Other abbreviations are as shown in Table 1.
